In a comparative study, two groups of patients suffering from
bronchial asthma or chronic obstructive
bronchitis were tested with the new broncholytic substance 7-(3-[2/24/k-dihydroxyphenyl-2-hydroxy-ethylamino]-propyl)-
theophylline (
reproterol, Bronchspasmin) versus the well proven
drug orciprenaline. Both preparations were administered for four weeks in doses of 3 x 20 mg/day (some patients received 6 x 10 mg/day). Different variables of the lung function were examined twice weekly prior to and 1 hr following ingestion of the substance (FVC, FEV1, Rt, IGV, Palpha02). On the basis of findings in above variables, both
reproterol and
orciprenaline showed very good and significant
broncholytic effects. The efficacy of
reproterol, however, proved to be significantly superior to that of
orciprenaline. This also has been confirmed in subjective reports of patients with regard to strength and duration of alleviation of their respiratory distress. Palpitation, slight
tremor of the fingers,
restlessness, pressure in the head and
dizziness were mentioned as side effects. These symptoms occurred fairly often with
orciprenaline, but relatively seldom with
reproterol. This difference between the preparations was highly significant. Following four weeks of administration, no tachyphylaxis was observed. In view of the submitted results,
reproterol represents, no doubt, a considerable addition to the presently available therapeutic collection of remedies for the treatment of obstructive airways diseases.